Evidence map›Paper›PMID 19366942›Full record

SynthesisCanadian family physician Medecin de famille canadien2009

Treating prediabetes with metformin: systematic review and meta-analysis.

Muriel Lily, Muriel Lilly, Marshall Godwin

Erratum issuedOpen access · greenAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC
In one paragraph

Synthesis in Canadian family physician Medecin de famille canadien, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 41 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 3 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. The Emerging Role of Prediabetes and Its Management: Focus on L-Arginine and a Survey in Clinical Practice.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023
    Review
  9. Review
  10. Metformin use among obese patients with prediabetes in Qassim, Saudi Arabia: An observational study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  11. Foods (Basel, Switzerland) · 2023
    Article
  12. Pesticide Exposure in Relation to the Incidence of Abnormal Glucose Regulation: A Retrospective Cohort Study.International journal of environmental research and public health · 2022
    Article
  13. Article
  14. Article
  15. Review of Metformin Use for Type 2 Diabetes Prevention.American journal of preventive medicine · 2018
    Review
  16. Review
  17. Glucose time series complexity as a predictor of type 2 diabetes.Diabetes/metabolism research and reviews · 2017
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Muriel LilyPrimary Healthcare Research Unit, Health Science Centre, 300 Prince Philip Drive, St John's, Newfoundland.
Muriel Lilly
Marshall Godwin
Primary HealthCare · MT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine if the use of metformin in people with prediabetes (impaired glucose tolerance or impaired fasting glucose) would prevent or delay the onset of frank type 2 diabetes mellitus. DATA SOURCES: MEDLINE was searched from January 1966 to the present, and articles meeting the selection criteria were hand searched. STUDY SELECTION: Randomized controlled trials that involved administration of metformin to delay or prevent type 2 diabetes in individuals with impaired glucose tolerance or impaired fasting glucose were included. Development of diabetes was a required outcome measure; follow-up time of at least 6 months was required. Three studies met these criteria. SYNTHESIS: The 3 studies varied in ethnicity of the population studied, in the rates of conversion to diabetes from prediabetes, and in the dose of metformin used. In general the studies were well done, although 2 of the 3 did not do true intention-to-treat analyses. A sensitivity analysis was completed by converting all data to intention-to-treat data and assuming a worst-case scenario for the people who were lost to follow-up.

conclusionMetformin decreases the rate of conversion from prediabetes to diabetes. This was true at higher dosage (850 mg twice daily) and lower dosage (250 mg twice or 3 times daily); in people of varied ethnicity; and even when a sensitivity analysis was applied to the data. The number needed to treat was between 7 and 14 for treatment over a 3-year period.

Indexed as

Administration, OralBlood GlucoseDiabetes Mellitus, Type 2Dose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHumansHypoglycemic AgentsMaleMetforminNewfoundland and LabradorPrediabetic StateRandomized Controlled Trials as TopicRisk AssessmentSensitivity and SpecificityBlood GlucoseHypoglycemic AgentsMetformin

Identifiers

PMID19366942
PMCPMC2669003
OpenAlexW2140110018

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.